Erratum: 15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE 2 /PPARγ-mediated activation of p21 WAF1/Cip1 (Oncogene (2014) 33 (1101-1112) DOI: 10.1038/onc.2013.69);15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE 2 /PPARγ-mediated activation of p21 WAF1/Cip1

Oncogene

Volumn 33, Issue 9, 2014, Pages 1101-1112

  Lu, D ^a,b   Han, C ^a   Wu, T ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TONGJI UNIVERSITY   (China)

Author keywords

15 hydroxyprostaglandin dehydrogenase (15 PGDH); 15 keto PGE2; hepatocellular carcinoma (HCC); liver; p21; PPARg

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 15 KETO PROSTAGLANDIN E2; ADENOVIRUS VECTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN DERIVATIVE; PROTEIN P21; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTAGLANDIN METABOLISM; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ADENOVIRIDAE; MUS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DINOPROSTONE; HEP G2 CELLS; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; PPAR GAMMA; PROLIFERATING CELL NUCLEAR ANTIGEN; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896691556     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.288     Document Type: Erratum

References (44)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73 e1.
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 2006; 6: 674-687.
4. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327.
5. Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 2006; 32: 28-44.
6. Breinig M, Schirmacher P, Kern MA. Cyclooxygenase-2 (COX-2)-A therapeutic target in liver cancer? Curr Pharm Des 2007; 13: 3305-3315.
7. Cervello M, Montalto G. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol 2006; 12: 5113-5121.
8. Claria J, Kent JD, Lopez-Parra M, Escolar G, Ruiz-Del-Arbol L, Gines P et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 2005; 41: 579-587.
9. Bosch-Marce M, Claria J, Titos E, Masferrer JL, Altuna R, Poo JL et al. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology 1999; 116: 1167-1175.
10. Vanchieri C. Vioxx withdrawal alarms cancer prevention researchers. J Natl Cancer Inst 2004; 96: 1734-1735.
11. Couzin J. Clinical trials. Nail-biting time for trials of COX-2 drugs. Science 2004; 306: 1673-1675.
12. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15.
13. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131: 1674-1682.
14. Tai HH. Prostaglandin catabolic enzymes as tumor suppressors. Cancer Metastasis Rev 2011; 30: 409-417.
15. Kaliberova LN, Kusmartsev SA, Krendelchtchikova V, Stockard CR, Grizzle WE, Buchsbaum DJ et al. Experimental cancer therapy using restoration of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression. Mol Cancer Ther 2009; 8: 3130-3139.
16. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 2006; 103: 12098-12102.
17. Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci USA 2009; 106: 9409-9413.
18. Tseng-Rogenski S, Gee J, Ignatoski KW, Kunju LP, Bucheit A, Kintner HJ et al. Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. Am J Pathol 2010; 176: 1462-1468.
19. Liu Z, Wang X, Lu Y, Han S, Zhang F, Zhai H et al. Expression of 15-PGDH is downregulated by COX-2 in gastric cancer. Carcinogenesis 2008; 29: 1219-1227.
20. Frank B, Hoeft B, Hoffmeister M, Linseisen J, Breitling LP, Chang-Claude J et al. Association of hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD) variants and colorectal cancer risk. Carcinogenesis 2011; 32: 190-196.
21. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006; 66: 7818-7823.
22. Huang G, Eisenberg R, Yan M, Monti S, Lawrence E, Fu P et al. 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res 2008; 68: 5040-5048.
23. Ding Y, Tong M, Liu S, Moscow JA, Tai HH. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005; 26: 65-72.
24. Chou WL, Chuang LM, Chou CC, Wang AH, Lawson JA, FitzGerald GA et al. Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of peroxisome proliferator-Activated receptor gamma activation. J Biol Chem 2007; 282: 18162-18172.
25. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005; 280: 3217-3223.
26. Backlund MG, Mann JR, Holla VR, Shi Q, Daikoku T, Dey SK et al. Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res 2008; 68: 9331-9337.
27. Tatsuwaki H, Tanigawa T, Watanabe T, Machida H, Okazaki H, Yamagami H et al. Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma. Cancer Sci 2010; 101: 550-558.
28. Wakimoto N, Wolf I, Yin D, O'Kelly J, Akagi T, Abramovitz L et al. Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. Cancer Res 2008; 68: 6978-6986.
29. Thiel A, Ganesan A, Mrena J, Junnila S, Nykanen A, Hemmes A et al. 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res 2009; 15: 4572-4580.
30. Eruslanov E, Kaliberov S, Daurkin I, Kaliberova L, Buchsbaum D, Vieweg J et al. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: A mechanism for immune evasion in cancer. J Immunol 2009; 182: 7548-7557.
31. Moore AE, Greenhough A, Roberts HR, Hicks DJ, Patsos HA, Williams AC et al. HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis 2009; 30: 1796-1804.
32. Tong M, Ding Y, Tai HH. Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. Carcinogenesis 2006; 27: 2170-2179.
33. Lim K, Han C, Xu L, Isse K, Demetris AJ, Wu T. Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells: Evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids. Cancer Res 2008; 68: 553-560.
34. Lim K, Han C, Dai Y, Shen M, Wu T. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther 2009; 8: 3046-3055.
35. Yang L, Amann JM, Kikuchi T, Porta R, Guix M, Gonzalez A et al. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res 2007; 67: 5587-5593.
36. Abbas T, Dutta A. p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-414.
37. Starostina NG, Kipreos ET. Multiple degradation pathways regulate versatile CIP/ KIP CDK inhibitors. Trends Cell Biol 2012; 22: 33-41.
38. Jung YS, Qian Y, Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal 2010; 22: 1003-1012.
39. Dotto GP. p21WAF1/CIP1: More than a break to the cell cycle? Biochemica Et Biophysica Acta 2000; 1471: M43-M56.
40. Rousseau D, Cannella D, Boulairs J, Fitzgerald P, Fotedar A, Fotedar R. Growth inhibition of CDK-cyclin and PCNA binding domains by p21 occurs by distinct mechanisms and is regulated by ubiquitinproteasome pathways. Oncogene 1999; 18: 4313.
41. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 1995; 374: 386-388.
42. Luo Y, Hurwitz J, Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995; 375: 159-161.
43. Kawai M, Rosen CJ. PPARgamma: A circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol 2010; 6: 629-636.
44. Tontonoz P, Spiegelman BM. Fat and beyond: The diverse biology of PPARgamma. Annu Rev Biochem 2008; 77: 289-312.